Publications

2018

Efficacy of Combination FDL169/FDL176 is Greater than Tezacaftor/Ivacaftor

Properties of F508del-CFTR Potentiator FDL176

Properties of F508del-CFTR Second Site Corrector FD2052160

2017 publications


2017

Distinguishing Properties of CFTR Potentiator FDL176

Preclinical in vitro Evaluation: Combination FD169/FDL176 is Superior to Tezacaftor/Ivacaftor

2016

Effect of Four Sets of Distinct Modulators on Non-F508del Mutations that Cause Cystic Fibrosis

Effect of Novel F508del-CFTR Modulator Combination FDL169 and FDL176 on Expression and Functional Activ

A New Combination of CFTR Modulators Corrects Processing and Reduces Chronic Inhibition of F508del-CFTR

Properties of a Novel F508del-CFTR Corrector FDL169

2015

Lung Partitioning of deltaF508-CFTR Corrector

Fixing ΔF508-CFTR – Bringing New Correctors into the Fold

2014

The Potentiator FD2033129 Does Not Chronically Reduce deltaF508 CFTR Function in Contrast to VX-770
New Pathways to CFTR Correction

2013

Discovery and Development of Novel deltaF508-CFTR Correctors

Combination Screen for CFTR Modulators at FDL

High Throughput Combination Screening for deltaF508-CFTR Modulation with Small Molecules

The Path to 30% and Beyond: Discovery and Development of Second Generation CFTR Modulators

Current Team Members

- Andrew Kolodziej
- Eric Lu
- Feng Li
- Iris Kwok
- Jenna Tagliaferri
- Jingwen Chai
- John Ferkany
- John Flatley
- Justin Chin
- Mario Gamboa
FDL would like to acknowledge the following individuals for their important contributions to our research efforts:

- Abhijeet Kanawade
- Adam Less
- Afia Dasgupta
- Ales Dostal
- A. Deshpande
- Bridget McCarthy Cole
- Brett Truitt
- B. Cole
- Castera Bresilla
- Chris Oalmann
- Claudia Ordonez
- David Finnegan
- Erin Layer
- Gene Barsukov
- Haibo Shang
- Jianmin Mao
- Jinliang Sui
- Kanwen Wang
- Karen Handley
- Luis Miranda
- Mayur Dudhedia
We’d love to hear it!